238 related articles for article (PubMed ID: 24136456)
1. Progressive multifocal leukoencephalopathy in multiple sclerosis.
Chalkley JJ; Berger JR
Curr Neurol Neurosci Rep; 2013 Dec; 13(12):408. PubMed ID: 24136456
[TBL] [Abstract][Full Text] [Related]
2. Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: A review.
Sharma K; Tolaymat S; Yu H; Elkhooly M; Jaiswal S; Jena A; Kakara M; Sriwastava S
J Neurol Sci; 2022 Dec; 443():120459. PubMed ID: 36283150
[TBL] [Abstract][Full Text] [Related]
3. Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps.
Zaheer F; Berger JR
Ther Adv Drug Saf; 2012 Oct; 3(5):227-39. PubMed ID: 25083238
[TBL] [Abstract][Full Text] [Related]
4. Progressive multifocal leukoencephalopathy and newer biological agents.
Berger JR
Drug Saf; 2010 Nov; 33(11):969-83. PubMed ID: 20925435
[TBL] [Abstract][Full Text] [Related]
5. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
Clifford DB; De Luca A; Simpson DM; Arendt G; Giovannoni G; Nath A
Lancet Neurol; 2010 Apr; 9(4):438-46. PubMed ID: 20298967
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies and progressive multifocal leukoencephalopathy.
Berger JR; Houff SA; Major EO
MAbs; 2009; 1(6):583-9. PubMed ID: 20073129
[TBL] [Abstract][Full Text] [Related]
7. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
8. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
[TBL] [Abstract][Full Text] [Related]
9. Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
Faulkner M
Expert Opin Drug Saf; 2015; 14(11):1737-48. PubMed ID: 26394704
[TBL] [Abstract][Full Text] [Related]
10. Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients.
Rossi F; Newsome SD; Viscidi R
Mol Cell Probes; 2015 Feb; 29(1):54-62. PubMed ID: 25483260
[TBL] [Abstract][Full Text] [Related]
11. Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
Bacchetta F; Mathias A; Schluep M; Du Pasquier R
Mult Scler; 2017 Feb; 23(2):300-303. PubMed ID: 28165319
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study.
Wüthrich C; Popescu BF; Gheuens S; Marvi M; Ziman R; Denq SP; Tham M; Norton E; Parisi JE; Dang X; Lucchinetti CF; Koralnik IJ
J Neuropathol Exp Neurol; 2013 Nov; 72(11):1043-51. PubMed ID: 24128680
[TBL] [Abstract][Full Text] [Related]
13. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.
Perkins MR; Ryschkewitsch C; Liebner JC; Monaco MC; Himelfarb D; Ireland S; Roque A; Edward HL; Jensen PN; Remington G; Abraham T; Abraham J; Greenberg B; Kaufman C; LaGanke C; Monson NL; Xu X; Frohman E; Major EO; Douek DC
PLoS Pathog; 2012; 8(11):e1003014. PubMed ID: 23144619
[TBL] [Abstract][Full Text] [Related]
14. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients.
Dahlhaus S; Hoepner R; Chan A; Kleiter I; Adams O; Lukas C; Hellwig K; Gold R
J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1068-74. PubMed ID: 23606731
[TBL] [Abstract][Full Text] [Related]
15. A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy.
Chahin S; Berger JR
J Neurovirol; 2015 Dec; 21(6):623-31. PubMed ID: 25404234
[TBL] [Abstract][Full Text] [Related]
16. Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
Baldwin KJ; Hogg JP
Curr Opin Neurol; 2013 Jun; 26(3):318-23. PubMed ID: 23493158
[TBL] [Abstract][Full Text] [Related]
17. The human JC polyomavirus (JCPyV): virological background and clinical implications.
Hirsch HH; Kardas P; Kranz D; Leboeuf C
APMIS; 2013 Aug; 121(8):685-727. PubMed ID: 23781977
[TBL] [Abstract][Full Text] [Related]
18. [Targeted therapy and progressive multifocal leukoencephalopathy (PML): PML in the era of monoclonal antibody therapies].
Takao M
Brain Nerve; 2013 Nov; 65(11):1363-74. PubMed ID: 24200614
[TBL] [Abstract][Full Text] [Related]
19. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
Boster AL; Nicholas JA; Topalli I; Kisanuki YY; Pei W; Morgan-Followell B; Kirsch CF; Racke MK; Pitt D
JAMA Neurol; 2013 Mar; 70(3):398-402. PubMed ID: 23338729
[TBL] [Abstract][Full Text] [Related]
20. Progressive multifocal leukoencephalopathy and JC Virus-related disease in modern neurology practice.
Carruthers RL; Berger J
Mult Scler Relat Disord; 2014 Jul; 3(4):419-30. PubMed ID: 25877052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]